ID.1
Item
diagnosis of breast cancer
boolean
C0011900 (UMLS CUI [1,1])
C0006142 (UMLS CUI [1,2])
ID.2
Item
metastatic disease
boolean
C0027627 (UMLS CUI [1])
ID.3
Item
hormone receptor status
boolean
C0019929 (UMLS CUI [1])
ID.4
Item
estrogen receptor- and progesterone receptor-negative
boolean
C0279756 (UMLS CUI [1,1])
C0279766 (UMLS CUI [1,2])
ID.5
Item
androgen receptor-positive
boolean
C2986463 (UMLS CUI [1])
ID.6
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
ID.7
Item
ecog performance status 0-3
boolean
C1520224 (UMLS CUI [1])
ID.8
Item
postmenopausal (> 60 years of age)
boolean
C0232970 (UMLS CUI [1])
ID.9
Item
leukocyte count > 3,000/ul
boolean
C0023508 (UMLS CUI [1])
ID.10
Item
absolute neutrophil count > 1,500/ul
boolean
C0200633 (UMLS CUI [1])
ID.11
Item
platelet count > 100,000/ul
boolean
C0032181 (UMLS CUI [1])
ID.12
Item
total bilirubin normal
boolean
C0858307 (UMLS CUI [1])
ID.13
Item
ast and alt < 2.5 times upper limit of normal
boolean
C3888966 (UMLS CUI [1,1])
C0151905 (UMLS CUI [1,2])
ID.14
Item
creatinine normal or creatinine clearance > 60 ml/min
boolean
C0860945 (UMLS CUI [1])
ID.15
Item
prior concurrent therapy:
boolean
C1514463 (UMLS CUI [1])
ID.16
Item
at least 4 weeks since prior chemotherapy
boolean
C1514457 (UMLS CUI [1])
ID.17
Item
at least 4 weeks since prior biologic therapy
boolean
C0278947 (UMLS CUI [1])
ID.18
Item
at least 4 weeks since prior radiotherapy
boolean
C0279134 (UMLS CUI [1])
ID.19
Item
at least 30 days since prior investigational agents
boolean
C1875319 (UMLS CUI [1])
ID.20
Item
no concurrent dehydroepiandrosterone or androstenedione supplements
boolean
C0011185 (UMLS CUI [1,1])
C0002860 (UMLS CUI [1,2])
ID.21
Item
no concurrent chemotherapy or radiotherapy
boolean
C0392920 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,3])
ID.22
Item
no concurrent hormone therapy or immunotherapy (including trastuzumab [herceptin®])
boolean
C0279025 (UMLS CUI [1,1])
C0021083 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,3])